Four small trials suggest cannabinoids may reduce diabetic nerve pain, but the evidence is too limited for firm conclusions | Research

The takeaway

A systematic review found only four small RCTs testing cannabinoids for diabetic peripheral neuropathy, with three showing significant pain reduction at THC doses around 16-18 mg/day, though the limited evidence prevents definitive conclusions.

People with diabetic neuropathy exploring treatment options, clinicians managing diabetic pain, and researchers designing future cannabinoid trials.

3 of 4 RCTs showed significant pain reduction

What the researchers found

Three of four RCTs reported statistically significant reductions in neuropathic pain with cannabinoid interventions compared to placebo. Vaporized or sublingual THC at approximately 16-18 mg/day was associated with clinically meaningful pain relief. One trial did not show superiority over placebo.

Why it matters

Diabetic peripheral neuropathy affects up to 50% of people with diabetes and is notoriously difficult to treat. Despite growing interest in cannabinoids for neuropathic pain, evidence specific to diabetic neuropathy is remarkably sparse.

The numbers in context

15,377 records screened, 35 full texts assessed, 4 RCTs included. THC doses of approximately 16-18 mg/day via vaporized or sublingual routes were associated with pain relief in two trials. Adverse effects included dizziness and cognitive symptoms, generally mild to moderate.

How the study worked

Systematic review searching PubMed, Google Scholar, Cochrane Library, and Scopus. Screened 15,377 records, assessed 35 full-text articles for eligibility, and included 4 RCTs in qualitative synthesis. Only studies conducted specifically in participants with diabetes and painful peripheral neuropathy were eligible.

What this study cannot tell us

Only four small, heterogeneous RCTs were available. Variability in formulations and comparators limits comparability. Risk of bias concerns across studies. The identified dose range should be viewed as hypothesis-generating, not as a recommendation.

How to read the evidence

Preliminary: systematic review found only four small, heterogeneous RCTs with variability in formulations and risk of bias concerns.

When this study was published

Published 2026.

The bigger picture

The fact that only four small trials exist despite decades of cannabinoid research highlights how little specific evidence exists for this common and debilitating condition. The preliminary dose range of 16-18 mg/day THC provides a starting point for future trials.

Questions still open

Would larger, well-designed RCTs confirm the 16-18 mg THC dose range? How do different cannabinoid formulations compare for diabetic neuropathy specifically? What are the long-term safety considerations for chronic use?

Common questions

Can cannabis help with diabetic nerve pain?

Three of four small clinical trials found cannabinoid-based therapies significantly reduced pain in diabetic peripheral neuropathy, but the evidence is too limited for firm conclusions.

What dose of THC was used for diabetic neuropathy?

Two trials found pain relief at approximately 16-18 mg/day of THC delivered via vaporized or sublingual routes, though these should be viewed as preliminary findings.

Read the original research

Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review.

Cannabis and cannabinoid research, 25785125261425444

View on PubMed ↗Publisher’s paper ↗

Citation

Sherman, Justin J; Riche, Daniel M. (2026). Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review.. Cannabis and cannabinoid research, 25785125261425444. https://doi.org/10.1177/25785125261425444